Advertisement

Subcutaneous botulinum toxin type A injections for provoked vestibulodynia: a randomized placebo-controlled trial and exploratory subanalysis

  • Inessa Diomande
  • Natalie Gabriel
  • Maki Kashiwagi
  • Gian-Piero Ghisu
  • JoEllen Welter
  • Daniel Fink
  • Mathias K. Fehr
  • Cornelia BetschartEmail author
General Gynecology
  • 51 Downloads

Abstract

Background

Previous studies using botulinum toxin type A (BT) to treat provoked vestibulodynia (PVD) reported conflicting findings, possibly attributable to singular injections or low doses. We assessed PVD treatment effectiveness with high-dose single injections of BT (50 or 100 units) versus placebo, and then repeat BT 100 U injections over 6 months.

Methods

This was a randomized, double-blind, three-arm, placebo-controlled study with 33 PVD patients. BT 50 U (arm A), 100 U (arm B) or saline (arm C) were injected subcutaneously into the dorsal vulvar vestibulum and pain was assessed after 3 months. The investigation proceeded as an unblinded exploratory analysis, in which symptomatic patients received a BT 100 U injection. Symptomatic patients in arm C received a second BT 100 U injection at the 6-month visit. Symptoms were measured at 3-month cycles using: (1) cotton swab-provoked visual analogue scale (VAS), (2) von Frey filaments, and (3) Marinoff dyspareunia scale.

Results

The three groups were comparable in terms of demographics and baseline clinical characteristics. Three months after the initial injection, no significant differences in pain were observed among the study arms, yet significant improvements occurred within all groups using the von Frey filaments test. Results from the exploratory analyses showed repeat injections of 100 U BT over 6 months led to significant pain reduction (VAS and von Frey filaments). Fifty-eight percent (7/12) of patients assessable after repeat injections were symptom-free or had ≥ 2 VAS reduction. Adverse events were minor and no serious adverse events occurred during the RCT or exploratory analysis.

Conclusions

PVD symptoms after one subcutaneous injection of BT (50 or 100 units) did not significantly differ compared to placebo, yet all three study arms experienced a reduction in pain 3 months after a single injection. Exploratory analyses indicated that repeat high-dose BT injections may significantly reduce pain over 6 months.

Trial registration

This trial was registered with the Swiss Medical Agency (reference number: 2007DR2102) in 2007.

Keywords

Provoked vestibulodynia Vulvodynia Botulinum toxin type A von Frey filaments Dyspareunia Sexual intercourse 

Abbreviations

BT

Botulinum toxin type A

IQR

Interquartile range

PVD

Provoked vestibulodynia

RCT

Randomized controlled trial

SD

Standard deviation

VAS

Visual analogue scale

Notes

Acknowledgements

We acknowledge the support of Dr. R. Bernhardt, Senior Manager Scientific Services, Allergan AG, Switzerland, for the supply of botulinum toxin type A without obligation or input into this clinical trial. We also acknowledge the support of Malgorzata Roos, PhD, Department of Biostatistics, University of Zurich for advice on statistical analyses, and pharmacist Dr. D. Fetz for managing the drug inventory and randomization process.

Author contributions

ID: data collection, analysis and manuscript writing. NG: protocol finalization, study initiation, and manuscript editing. MK: concept idea, study protocol, and manuscript editing. GPG: patient recruitment, and manuscript editing. JW: data analysis, and manuscript editing. DF: concept idea, and manuscript editing. MKF: concept idea, study protocol, data analysis, manuscript writing and editing. CB: study organization, reports to authorities (Swissmedic, KEK), data collection and analysis, and manuscript writing. MKF and CB contributed equally to the manuscript.

Compliance with ethical standards

Ethics approval and consent to participate

Study design was approved by Ethics Commission of Zurich (KEK-ZH StV 16/2005). All patients provided written consent to participate.

Availability of data and material

The datasets used and/or analyzed during this current study are available from the corresponding author on reasonable request.

Conflict of interest

The authors declare that they have no competing interests.

Disclosure of funding support

The drug botulinum toxin type A was provided free of charge by Allergan AG, Zurich, Switzerland. The role of Allergan AG was solely in provision of the medication. The company was not involved in the study design; data collection, analysis, or interpretation; writing of the report; or decision to submit the paper for publication.

References

  1. 1.
    McKay M (1989) Vulvodynia: a multifactorial clinical problem. Arch Dermatol 125:256–262CrossRefGoogle Scholar
  2. 2.
    Bornstein J, Goldstein AT, Stockdale CK, Bergeron S, Pukall C, Zolnoun D, Coady D (2016) 2015 ISSVD, ISSWSH, and IPPS consensus terminology and classification of persistent vulvar pain and vulvodynia. J Low Genit Tract Dis. 20(2):126–130.  https://doi.org/10.1097/LGT.0000000000000190 CrossRefGoogle Scholar
  3. 3.
    Harlow BL, Stewart EG (2003) A population-based assessment of chronic unexplained vulvar pain: have we underestimated the prevalence of vulvodynia? J Am Med Women Assoc 58(2):82–88Google Scholar
  4. 4.
    Reed BD, Harlow SD, Sen A et al (2012) Prevalence and demographic characteristics of vulvodynia in a population-based sample. Am J Obstet Gynecol 206(170):e1–e9.  https://doi.org/10.1016/j.ajog.2011.08.012 CrossRefGoogle Scholar
  5. 5.
    Sadownik LA (2014) Etiology, diagnosis, and clinical management of vulvodynia. Int J Womens Health 6:437–449.  https://doi.org/10.2147/IJWH.S37660 CrossRefGoogle Scholar
  6. 6.
    Haefner HK (2007) Report of the International Society for the Study of Vulvovaginal Disease terminology and classification of vulvodynia. J Low Genit Tract Dis 11(1):48–49CrossRefGoogle Scholar
  7. 7.
    Sutton JT, Bachmann GA, Arnold LD et al (2008) Assessment of vulvodynia symptoms in a sample of US women: a follow-up national incidence survey. J Womens Health 17:1285–1292.  https://doi.org/10.1089/jwh.2007.0677 CrossRefGoogle Scholar
  8. 8.
    Stockdale CK, Lawson HW (2014) 2013 vulvodynia guideline update. J Low Genit Tract Dis. 18(2):93–100.  https://doi.org/10.1097/LGT.0000000000000021 CrossRefGoogle Scholar
  9. 9.
    Tommola P, Unkila-Kallio L, Paetau A et al (2016) Immune activation enhances epithelial nerve growth in provoked vestibulodynia. Am J Obstet Gynecol 215(6):768.e1–768.e8.  https://doi.org/10.1016/j.ajog.2016.07.037 CrossRefGoogle Scholar
  10. 10.
    Aoki KR (2003) Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 43(Suppl 1):S9–S15CrossRefGoogle Scholar
  11. 11.
    Smith CP (2004) Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology 64(5):871–875CrossRefGoogle Scholar
  12. 12.
    Tirumuru S, Al-Kurdi D, Latthe P (2010) Intravesical botulinum toxin A injections in the treatment of painful bladder syndrome/interstitial cystitis: a systematic review. Int Urogynecol J 21(10):1285–1300.  https://doi.org/10.1007/s00192-010-1162-9 CrossRefGoogle Scholar
  13. 13.
    Jabbari B, Maher N, Difasio MP (2003) Botulinum toxin improved burning pain and allodynia in two patients with spinal cord pathology. Pain Med. 4:206–210CrossRefGoogle Scholar
  14. 14.
    Bohm-Starke N, Hilliges M, Falconer C et al (1999) Neurochemical characterization of the vestibular nerves in women with vulvar vestibulitis syndrome. Gynecol Obstet Invest. 48:270–275CrossRefGoogle Scholar
  15. 15.
    Westrom LV, Willen R (1998) Vestibular nerve fiber proliferation in vulvar vestibulitis syndrome. Obstet Gynecol 91:572–576Google Scholar
  16. 16.
    Yoon H, Chung WS, Shim BS (2007) Botulinum toxin A for the management of vulvodynia. Int J Impot Res 19:84–87CrossRefGoogle Scholar
  17. 17.
    Gunter J, Brewer A, Tawfik O (2004) Botulinum toxin A for vulvodynia: a case report. J Pain 5:238–240CrossRefGoogle Scholar
  18. 18.
    Dykstra DD, Presthus J (2006) Botulinum toxin type A for the treatment of provoked vestibulodynia: an open-label, pilot study. J Reprod Med 51:467–470Google Scholar
  19. 19.
    Brown CS, Glazer HI, Vogt V et al (2006) Subjective and objective outcomes of botulinum toxin type A treatment in vestibulodynia: pilot data. J Reprod Med 51:635–641Google Scholar
  20. 20.
    Petersen CD, Giraldi A, Lundvall L et al (2009) Botulinum toxin type A—a novel treatment for provoked vestibulodynia? Results from a randomized, placebo controlled, double blinded study. J Sex Med. 6(9):2523–2537.  https://doi.org/10.1111/j.1743-6109.2009.01378.x CrossRefGoogle Scholar
  21. 21.
    Pelletier F, Parratte B, Penz S et al (2011) Efficacy of high doses of botulinum toxin A for treating provoked vestibulodynia. Br J Dermatol 164:617–622.  https://doi.org/10.1111/j.1365-2133.2011.10235.x Google Scholar
  22. 22.
    Friedrich EGJ (1987) Vulvar vestibulitis syndrome. J. Reprod. Med 32:110–114Google Scholar
  23. 23.
    Ojo OO, Fernandez HH (2015) Is it time for flexibility in botulinum inter-injection intervals? Toxicon 107(Pt A):72–76.  https://doi.org/10.1016/j.toxicon.2015.09.037 CrossRefGoogle Scholar
  24. 24.
    Rowbotham MC (2001) What is a “clinically meaningful” reduction in pain? Pain 94(2):131–132CrossRefGoogle Scholar
  25. 25.
    Nguyen RH, Mathur C, Wynings EM et al (2015) Remission of vulvar pain among women with primary vulvodynia. Low Genit Tract Dis. 19(1):62–67.  https://doi.org/10.1097/LGT.0000000000000041 CrossRefGoogle Scholar
  26. 26.
    Danielsson I, Sjöberg I, Stenlund H et al (2003) Prevalence and incidence of prolonged and severe dyspareunia in women: results from a population study. Scand J Public Health 31(2):113–118CrossRefGoogle Scholar
  27. 27.
    Romito S, Bottanelli M, Pellegrini M et al (2004) Botulinum toxin for the treatment of genital pain syndromes. Gynecol Obstet Invest 58(3):164–167CrossRefGoogle Scholar
  28. 28.
    Bachour CC, Bachmann GA, Foster DC, Wan JY, Rawlinson LA, Brown CS (2017) Gabapentin Study Group (GABAgroup) Recruitment methods in a clinical trial of provoked vulvodynia: predictors of enrollment. Clinical Trials 14(1):103–108.  https://doi.org/10.1177/1740774516663461 CrossRefGoogle Scholar
  29. 29.
    Lindstöm S, Kvist L (2015) Treatment of provoked vulvodynia in a Swedish cohort using desensitization exercises and cognitive behavioral therapy. BMC Women’s Health 15:108.  https://doi.org/10.1186/s12905-015-0265-3 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Gynecology, University HospitalUniversity of ZurichZurichSwitzerland
  2. 2.Department of Obstetrics and GynecologyCantonal Hospital FrauenfeldFrauenfeldSwitzerland
  3. 3.Department of Obstetrics and GynecologyTriemli HospitalZurichSwitzerland
  4. 4.GynosenseWomen’s Health CenterUsterSwitzerland

Personalised recommendations